Threshold begins Phase III trial of TH-302 to treat lung cancer
US-based Threshold Pharmaceuticals has started a Phase II clinical trial of its investigational hypoxia-activated prodrug, TH-302, in combination with pemetrexed to treat patients with advanced non-squamous non-small cell lung cancer (NSCLC).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Alimta | Cancer | Cancer & Oncology | Clinical Trials | Lung Cancer | Non-Small Cell Lung Cancer | Pharmaceuticals